- Home
- NGG vs BSX Comparison
NGG vs BSX Comparison
Compare NGG & BSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NGG | BSX |
|---|---|---|
| Founded | 1990 | 1979 |
| Country | United Kingdom | United States |
| Employees | 31645 | N/A |
| Industry | Natural Gas Distribution | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.4B | 93.4B |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | NGG | BSX |
|---|---|---|
| Price | $83.47 | $45.28 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 3 | 22 |
| Target Price | N/A | ★ $93.18 |
| AVG Volume (30 Days) | 1.2M | ★ 20.4M |
| Earning Date | 05-14-2026 | 04-22-2026 |
| Dividend Yield | ★ 3.59% | N/A |
| EPS Growth | N/A | ★ 55.20 |
| EPS | N/A | ★ 0.90 |
| Revenue | N/A | ★ $9,076,000,000.00 |
| Revenue This Year | N/A | $11.85 |
| Revenue Next Year | $11.17 | $10.16 |
| P/E Ratio | $115.91 | ★ $49.58 |
| Revenue Growth | N/A | ★ 12.49 |
| 52 Week Low | $67.52 | $42.25 |
| 52 Week High | $94.64 | $109.50 |
Technical Indicators
Market Signals| Indicator | NGG | BSX |
|---|---|---|
| Relative Strength Index (RSI) | 52.67 | 41.66 |
| Support Level | $77.70 | N/A |
| Resistance Level | $84.10 | $50.14 |
| Average True Range (ATR) | 1.19 | 1.39 |
| MACD | 0.30 | 0.41 |
| Stochastic Oscillator | 87.08 | 60.70 |
Price Performance
Historical ComparisonAbout NGG National Grid Transco PLC National Grid PLC (NEW)
National Grid owns and operates the electric transmission system in England and Wales. It sold the bulk of its UK gas transmission business in fiscal 2023 to fund the acquisition of PPL's UK power distribution assets. In the Northeastern United States, it serves electricity and gas customers combined in three states. It also owns regulated transmission electricity networks in the United States, metering services and merchant transmission lines in the UK.
About BSX Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.